Cargando…

Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis

BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). OBJECTIVES: To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC. PATIENTS AND METHODS: We ret...

Descripción completa

Detalles Bibliográficos
Autores principales: Ohki, Takamasa, Sato, Koki, Yamagami, Mari, Ito, Daisaku, Yamada, Tomoharu, Kawanishi, Koki, Kojima, Kentaro, Seki, Michiharu, Toda, Nobuo, Tagawa, Kazumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621710/
https://www.ncbi.nlm.nih.gov/pubmed/26446004
http://dx.doi.org/10.1007/s40261-015-0333-3
_version_ 1782397484810633216
author Ohki, Takamasa
Sato, Koki
Yamagami, Mari
Ito, Daisaku
Yamada, Tomoharu
Kawanishi, Koki
Kojima, Kentaro
Seki, Michiharu
Toda, Nobuo
Tagawa, Kazumi
author_facet Ohki, Takamasa
Sato, Koki
Yamagami, Mari
Ito, Daisaku
Yamada, Tomoharu
Kawanishi, Koki
Kojima, Kentaro
Seki, Michiharu
Toda, Nobuo
Tagawa, Kazumi
author_sort Ohki, Takamasa
collection PubMed
description BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). OBJECTIVES: To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC. PATIENTS AND METHODS: We retrospectively analyzed 95 advanced HCC patients treated with TACE between July 2008 and December 2012 at our institution. Twenty-four patients received TACE followed by sorafenib within 14 days (S-TACE) and 71 received TACE alone. Progression-free survival (PFS) and cumulative survival from the time of non-responsiveness to TACE were compared between groups and predictive factors for PFS were analyzed. RESULTS: The median patient age was 72.2 years and 74 patients were male (77.9 %). Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04). The number of prior treatments was significantly higher in the S-TACE group. Other baseline variables were similar. There were two severe adverse events in the S-TACE group and none in the TACE-alone group. Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Adjusting for significant factors in univariate analysis, multivariate analysis indicated that sorafenib administration, tumor size, and alanine transaminase were independent predictors of PFS. CONCLUSION: TACE followed by sorafenib significantly improved PFS and survival in patients with advanced HCC unresponsive to TACE.
format Online
Article
Text
id pubmed-4621710
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-46217102015-10-30 Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis Ohki, Takamasa Sato, Koki Yamagami, Mari Ito, Daisaku Yamada, Tomoharu Kawanishi, Koki Kojima, Kentaro Seki, Michiharu Toda, Nobuo Tagawa, Kazumi Clin Drug Investig Original Research Article BACKGROUND: Sorafenib might prevent hepatocellular carcinoma (HCC) recurrence caused by the promotion of neoangiogenesis after transarterial chemoembolization (TACE). OBJECTIVES: To evaluate the efficacy and safety of TACE followed by sorafenib for treating advanced HCC. PATIENTS AND METHODS: We retrospectively analyzed 95 advanced HCC patients treated with TACE between July 2008 and December 2012 at our institution. Twenty-four patients received TACE followed by sorafenib within 14 days (S-TACE) and 71 received TACE alone. Progression-free survival (PFS) and cumulative survival from the time of non-responsiveness to TACE were compared between groups and predictive factors for PFS were analyzed. RESULTS: The median patient age was 72.2 years and 74 patients were male (77.9 %). Although median tumor size was similar between groups, the mean tumor number was significantly higher in the S-TACE versus TACE-alone group (16 vs. 8, P = 0.04). The number of prior treatments was significantly higher in the S-TACE group. Other baseline variables were similar. There were two severe adverse events in the S-TACE group and none in the TACE-alone group. Median PFS (189 vs. 106 days, P = 0.02) and median overall survival time (861 vs. 467 days, P = 0.01) from the time of non-responsiveness to TACE were significantly longer with S-TACE than TACE alone. Adjusting for significant factors in univariate analysis, multivariate analysis indicated that sorafenib administration, tumor size, and alanine transaminase were independent predictors of PFS. CONCLUSION: TACE followed by sorafenib significantly improved PFS and survival in patients with advanced HCC unresponsive to TACE. Springer International Publishing 2015-10-08 2015 /pmc/articles/PMC4621710/ /pubmed/26446004 http://dx.doi.org/10.1007/s40261-015-0333-3 Text en © The Author(s) 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Research Article
Ohki, Takamasa
Sato, Koki
Yamagami, Mari
Ito, Daisaku
Yamada, Tomoharu
Kawanishi, Koki
Kojima, Kentaro
Seki, Michiharu
Toda, Nobuo
Tagawa, Kazumi
Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
title Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
title_full Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
title_fullStr Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
title_full_unstemmed Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
title_short Efficacy of Transcatheter Arterial Chemoembolization Followed by Sorafenib for Intermediate/Advanced Hepatocellular Carcinoma in Patients in Japan: A Retrospective Analysis
title_sort efficacy of transcatheter arterial chemoembolization followed by sorafenib for intermediate/advanced hepatocellular carcinoma in patients in japan: a retrospective analysis
topic Original Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621710/
https://www.ncbi.nlm.nih.gov/pubmed/26446004
http://dx.doi.org/10.1007/s40261-015-0333-3
work_keys_str_mv AT ohkitakamasa efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT satokoki efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT yamagamimari efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT itodaisaku efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT yamadatomoharu efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT kawanishikoki efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT kojimakentaro efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT sekimichiharu efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT todanobuo efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis
AT tagawakazumi efficacyoftranscatheterarterialchemoembolizationfollowedbysorafenibforintermediateadvancedhepatocellularcarcinomainpatientsinjapanaretrospectiveanalysis